/ /

  • linkedin
  • Increase Font
  • Sharebar

    Ophthotech, Novartis join for wet AMD treatment


    New York—Ophthotech Corp. has entered into an ex-U.S. licensing and commercialization agreement with Novartis Pharmaceuticals that will focus on the treatment of wet age-related macular degeneration (AMD).

    Under the agreement, Ophthotech grants Novartis exclusive rights to commercialize its lead product candidate, Fovista, in markets outside the United States, while Ophthotech retains sole rights to commercialize its drug in the United States.

    Potential payments to Ophthotech under the agreement could total more than $1 billion in upfront and milestone payments, not including future royalties, according to the company.

    Ophthotech will continue to lead the global phase III wet AMD pivotal clinical program of the drug, which is expected to have initial, top-line data available in 2016.

    Rose Schneider Krivich
    Rose is the content specialist for Medical Economics.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results